Related Experiment Video
Updated: Sep 6, 2025
10:53
Anionic Polymerization of an Amphiphilic Copolymer for Preparation of Block Copolymer Micelles Stabilized by π-π Stacking Interactions
Published on: October 10, 2016
14.1K
Block Co-PolyMOC Micelles and Structural Synergy as Composite Nanocarriers
Lang Wang1, Zhongmin Geng2,3, Yannis Y L Ho1
1Department of Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong SAR 999077, China.
ACS Applied Materials & Interfaces
|June 24, 2022
Summary
New block co-polyMOC micelles (BCPMs) offer stable drug delivery. These composite nanoparticles prevent premature drug release, enhancing bioavailability and improving cancer treatment efficacy in vivo.
Area of Science:
- Materials Science
- Nanotechnology
- Biomedical Engineering
Background:
- Conventional micelles made of amphiphilic block copolymers (BCPs) often break apart when diluted, leading to premature drug release and reduced bioavailability.
- This instability limits their effectiveness as nanocarriers for drug delivery.
Purpose of the Study:
- To develop a novel composite micellar nanoparticle, termed block co-polyMOC micelles (BCPMs), with enhanced stability against dilution.
- To investigate the potential of BCPMs as nanocarriers for improved drug delivery, particularly for anticancer drugs.
Main Methods:
- Fabrication of BCPMs using a stepwise assembly strategy combining metal-organic cages (MOCs) and BCPs.
- Characterization of the unimolecular core-shell structure and stability of BCPMs.
- In vivo evaluation of BCPMs as nanocarriers for anticancer drugs, assessing blood circulation, biodistribution, and treatment efficacy.
Main Results:
- BCPMs exhibit remarkable stability against dilution due to the synergistic interaction between the MOC core and the BCP shell.
- BCPMs demonstrated extended blood circulation and favorable biodistribution when used for drug delivery.
- An improved anticancer treatment efficacy was observed in vivo using BCPMs as nanocarriers.
Conclusions:
- BCPMs represent a robust and tunable platform for nanomedicine, overcoming the limitations of conventional BCP micelles.
- The integration of MOCs and BCPs offers a versatile approach for developing advanced drug delivery systems with enhanced therapeutic outcomes.
